Selecting the first chemical molecule inhibitor of HSP110 for colorectal cancer therapy
Gustavo Jabor Gozzi(Inserm), Carmen Garrido(Inserm)
Cited by 64
Related Papers
Restoring Anticancer Immune Response by Targeting Tumor-Derived Exosomes With a HSP70 Peptide Aptamer
|JNCI Journal of the National Cancer Institute|2015|196
Lipidomic profiling of exosomes from colorectal cancer cells and patients reveals potential biomarkers
|Molecular Oncology|2022|83
CBP-HSF2 structural and functional interplay in Rubinstein-Taybi neurodevelopmental disorder
|Nature Communications|2022|20
CBP/EP300-dependent acetylation and stabilization of HSF2 are compromised in the rare disorder, Rubinstein-Taybi syndrome
|bioRxiv (Cold Spring Harbor Laboratory)|2018|2